Evidence map›Paper›PMID 28400167›Full record

ArticleEuropean urology2018

Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.

R Jeffrey Karnes, Voleak Choeurng, Ashley E Ross, Edward M Schaeffer, Eric A Klein, Stephen J Freedland, Nicholas Erho, Kasra Yousefi, Mandeep Takhar, Elai Davicioni and 2 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Prostate cancer.Nature reviews. Disease primers · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

R Jeffrey KarnesDepartment of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Voleak ChoeurngGenomeDx Biosciences, Vancouver, BC, Canada.
Ashley E RossJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Edward M SchaefferJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA; Department of Urology, Northwestern University School of Medicine, Chicago, IL, USA.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Stephen J FreedlandSurgery Section, Durham Veteran Affairs Medical Center, Durham, NC, USA; Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Nicholas ErhoGenomeDx Biosciences, Vancouver, BC, Canada.
Kasra YousefiGenomeDx Biosciences, Vancouver, BC, Canada.
Mandeep TakharGenomeDx Biosciences, Vancouver, BC, Canada.
Elai DavicioniGenomeDx Biosciences, Vancouver, BC, Canada.
Matthew R CooperbergDepartment of Urology and Epidemiology and Biostatistics, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.
Bruce J TrockJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: btrock@jhmi.edu.
Genome British Columbia · CAJohns Hopkins University · USCleveland Clinic · USDurham VA Medical Center · USMayo Clinic · USNorthwestern University · USUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
NCI NIH HHS P50 CA058236NCI NIH HHS P50 CA180995
6 · The paper itself

Abstract

backgroundRisk of prostate cancer-specific mortality (PCSM) is highly variable for men with adverse pathologic features at radical prostatectomy (RP); a majority will die of other causes. Accurately stratifying PCSM risk can improve therapy decisions.

objectiveValidate the 22 gene Decipher genomic classifier (GC) to predict PCSM in men with adverse pathologic features after RP. DESIGN, SETTING, AND

participantsMen with adverse pathologic features: pT3, pN1, positive margins, or Gleason score >7 who underwent RP in 1987-2010 at Johns Hopkins, Cleveland Clinic, Mayo Clinic, and Durham Veteran's Affairs Hospital. We also analyzed subgroups at high risk (prostate-specific antigen >20 ng/ml, RP Gleason score 8-10, or stage >pT3b), or very high risk of PCSM (biochemical recurrence in<2 yr [BCR2], or men who developed metastasis after RP [MET]). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Logistic regression evaluated the association of GC with PCSM within 10 yr of RP (PCSM10), adjusted for the Cancer of the Prostate Risk Assessment Postsurgical Score (CAPRA-S). GC performance was evaluated with area under the receiver operating characteristic curve (AUC) and decision curves. RESULTS AND LIMITATIONS: Five hundred and sixty-one men (112 with PCSM10), median follow-up 13.0 yr (patients without PCSM10). For high GC score (> 0.6) versus low-intermediate (≤ 0.6), the odds ratio for PCSM10 adjusted for CAPRA-S was 3.91 (95% confidence interval: 2.43-6.29), with AUC=0.77, an increase of 0.04 compared with CAPRA-S. Subgroup odds ratios were 3.96, 3.06, and 1.95 for high risk, BCR2, or MET, respectively (all p<0.05), with AUCs 0.64-0.72. GC stratified cumulative PCSM10 incidence from 2.8% to 30%. Combined use of case-control and cohort data is a potential limitation.

conclusionsIn a large cohort with the longest follow-up to date, Decipher GC demonstrated clinically important prediction of PCSM at 10 yr, independent of CAPRA-S, in men with adverse pathologic features, BCR2, or MET after RP. PATIENT SUMMARY: Decipher genomic classifier may improve treatment decision-making for men with adverse or high risk pathology after radical prostatectomy.

Indexed as

GenomicsRisk AssessmentAgedHumansMaleMiddle AgedPrognosisProstatic NeoplasmsAdverse pathologic featuresCAPRA-SGenomic classifierProstate cancer-specific mortalityRadical prostatectomy

Identifiers

PMID28400167
PMCPMC5632569
OpenAlexW2604768144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.